For the Quarter Ending March 2026
Rifaximin Prices in APAC
- In China, the Rifaximin Price Index rose by 2.64% quarter-over-quarter due to tighter output and exports.
- The average Rifaximin price for the quarter was approximately USD 124366.67/MT, reflecting mixed hospital demand.
- Tighter availability reduced Rifaximin Spot Price volatility, prompting selective restocking among regional formulators and traders.
- Rifaximin Production Cost Trend showed upward pressure from higher rifamycin SV import costs and steam expenses.
- Rifaximin Demand Outlook strengthened offshore as India and Brazil increased tenders, supporting firmer export negotiations.
- Inventory drawdowns left the Rifaximin Price Index more responsive to booking flows and short-term supplier discipline.
- Rifaximin Price Forecast points to limited near-term upside given balanced supply, though geopolitical risks remain.
- Operational audits and environmental inspections intermittently disrupted output, tightening spot availability and supporting short-term bullish sentiment.
Why did the price of Rifaximin change in March 2026 in APAC?
- Domestic production curbs from environmental audits reduced output, shrinking inventories and lifting sellers' negotiating leverage.
- Rifamycin SV import delays, higher steam energy expenses raised conversion costs, pressuring margins and offers.
- Export bookings from India and Brazil tightened spot availability, accelerating forward purchases and supporting rallies.
Rifaximin Prices in Europe
- In Germany, the Rifaximin Price Index rose by 2.66% quarter-over-quarter, reflecting tighter import availability recently
- The average Rifaximin price for the quarter was approximately USD 124473.33/MT, supporting measured replenishment activity.
- Rifaximin Spot Price firmed as container shortages and higher cold-chain handling pushed landed costs for lots.
- Rifaximin Price Forecast shows tightness driven by constrained fermentation capacity and selective restocking by distributors.
- Rifaximin Production Cost Trend elevated due to wastewater treatment compliance costs and increased fermentation expenses.
- Rifaximin Demand Outlook remains supportive from prescription volumes and seasonal traveler prophylaxis ahead of Easter
- Rifaximin Price Index reflected stronger offers as import quotas tightened and buyers prioritized assured supply
- Inventories remained stable, limiting upside, while exporters offered disciplined nominations, sustaining narrow range-bound trading conditions
Why did the price of Rifaximin change in March 2026 in Europe?
- Tighter export allocations from India, Italy, and China reduced shipments, constraining supply into German ports.
- Higher cold-chain handling premiums, customs clearance delays, and freight rates increased landed costs in March
- Sustained mid-single-digit prescription demand and pre-Easter restocking kept buyers active, supporting upward price momentum firmly
Rifaximin Prices in North America
- In the USA, the Rifaximin Price Index rose by 2.64% quarter-over-quarter, driven by stronger prescriptions and restocking.
- The average Rifaximin price for the quarter was approximately USD 124476.67/MT, reflecting balanced fundamentals overall.
- Rifaximin Spot Price liquidity remained limited in Los Angeles, constraining aggressive buying and bid-ask spreads.
- Rifaximin Price Forecast indicates modest volatility as freight and prescription trends drive short-term directional movement.
- Rifaximin Production Cost Trend rose because container freight and insurance premiums increased the landed cost components.
- Rifaximin Demand Outlook remains constructive with mid-single-digit prescription growth and measured wholesaler restocking activity ongoing.
- Inventory draws left distributor coverage under four weeks, increasing Rifaximin Price Index sensitivity to delays.
- Suppliers maintained disciplined offers with selective forward sales, keeping transaction volumes controlled while limiting corrections.
Why did the price of Rifaximin change in March 2026 in North America?
- Sharp Shanghai to Los Angeles freight increases raised landed costs, translating into higher CFR offers.
- Distributor inventories under four weeks forced prompt restocking, supporting sellers' stronger pricing discipline despite production.
- Sustained prescription growth and preparatory buying ahead of second-quarter seasonality increased demand pressure for wholesalers.
For the Quarter Ending December 2025
North America
- In the USA, the Rifaximin Price Index rose by 5.86% quarter-over-quarter, reflecting higher landed costs from China.
- The average Rifaximin price for the quarter was approximately USD 279185.00/MT per CFR Los Angeles.
- Rifaximin Spot Price firmed on controlled exports and steady shipments into West Coast distribution networks.
- Rifaximin Price Forecast indicates gradual modest increases as buyers advance orders ahead of reimbursement adjustments.
- Rifaximin Production Cost Trend showed stability overall, with localized cost pressure from Chinese manufacturing disruptions.
- Rifaximin Demand Outlook remained resilient owing to steady prescriptions and brand-driven offtake supporting firm offers.
- Rifaximin Price Index benefited from supplier offers and limited spot discounting despite softer freight costs.
- Inventory and export demand balanced availability, while port operations normalized, sustaining narrow upward price momentum.
Why did the price of Rifaximin change in December 2025 in North America?
- Buyers' advanced orders anticipating reimbursement changes, allowing exporters to pass a modest premium onto CFR invoices.
- Stable supply from Italy and India, declining freight rates, yet sellers maintained firm contract offers.
- Consistent prescription demand and brand exclusivity reduced discounting, supporting price firmness despite flat production economics.
APAC
- In China, the Rifaximin Price Index rose by 5.87% quarter-over-quarter, driven by export strength globally.
- The average Rifaximin price for the quarter was approximately USD 279100.00/MT, supporting measured seller discipline.
- Rifaximin Spot Price firmed modestly as Shanghai free-trade warehouses kept moderate stocks and steady shipments.
- Rifaximin Production Cost Trend rose as rifamycin SV import costs and euro strength pressured converters.
- Rifaximin Demand Outlook stayed constructive as hospital tenders and international buyers maintained disciplined restocking schedules.
- Rifaximin Price Forecast suggests a mild upward trajectory as exporters hold firm offers amid steady offtake.
- Rifaximin Price Index movements were muted by balanced inventories and normalized reefer freight on lanes.
- Zhejiang and Jiangsu plants operated near capacity, preserving export volumes while avoiding environmental compliance-related shutdowns.
Why did the price of Rifaximin change in December 2025 in APAC?
- Export call-offs from India and Brazil increased in December, tightening availability despite steady domestic output.
- Firmer rifamycin SV feedstock and stronger euro raised conversion costs, leading producers lift FOB offers.
- Shanghai port normalization and steady reefer freight avoided bottlenecks, allowing increased loading and timely shipments.
Europe
- In Germany, the Rifaximin Price Index rose by 5.85% quarter-over-quarter, driven by Chinese production costs.
- The average Rifaximin price for the quarter was approximately USD 279173.33/MT, reflecting Hamburg landed costs.
- Rifaximin Spot Price liquidity was thin, while the Price Index firmed on imports and restocking.
- Rifaximin Price Forecast shows gains as Rifaximin Production Cost Trend sustains upward pressure from intermediates.
- Rifaximin Demand Outlook remains positive, supporting the Price Index as prescriptions and distributor offtake grow.
- Rifaximin Price Index sensitivity to currency and logistics compelled importers to absorb costs, constraining pass-through.
- Major origins Italy, India, and China operated normally, exporters adjusted offers reflecting marginally tighter inventories.
- Forward buying supported moderate gains; Rifaximin Price Forecast and Spot Price outlook suggest gradual firming.
Why did the price of Rifaximin change in December 2025 in Europe?
- Elevated Asian production costs increased FOB levels, transmitting higher landed costs into Germany's import market.
- Logistics friction and handling premiums at Hamburg lengthened lead times and increased CFR landed-price components.
- Solid prescription demand and distributor restocking, constrained by rebate rules, supported steady offtake without pass-through.
For the Quarter Ending September 2025
North America
- In USA, the Rifaximin Price Index rose by 0.08% quarter-over-quarter, reflecting marginal forward buying activity.
- The average Rifaximin price for the quarter was approximately USD 263728.33/MT, based on invoiced imports.
- Rifaximin Spot Price remained subdued with stable supply, keeping the Rifaximin Price Index largely flat.
- Rifaximin Price Forecast indicates upward bias as Rifaximin Production Cost Trend sees persistent inflationary pressure.
- Rifaximin Demand Outlook points to steady healthcare offtake supporting the Price Index through seasonal cycles.
- Inventory buffers drawn earlier limited urgent imports, reducing pressure on the Rifaximin Price Index short-term.
- Major supplier operational continuity maintained, while freight volatility influenced Rifaximin Production Cost Trend and costs.
- Market participants adopt cautious buying; Rifaximin Price Forecast expects controlled rises amid measured replenishment activity.
Why did the price of Rifaximin change in September 2025 in North America?
- Precautionary forward buying amid tariff uncertainty temporarily increased inbound demand, nudging prices slightly upward recently.
- Elevated inventories from earlier strategic imports reduced replenishment urgency, placing downward pressure on spot Price Index.
- Logistics stability with minor port delays increased landed costs modestly, influencing near-term Price Index movement.
APAC
- In China, the Rifaximin Price Index rose by 0.10% quarter-over-quarter, supported by stable export interest.
- The average Rifaximin price for the quarter was approximately USD 263633.33/MT, reflecting balanced market conditions.
- Producers reported manageable inventories and balanced shipments, keeping the Rifaximin Spot Price stable through September.
- Outlook indicates modest upside as the Rifaximin Price Forecast factors steady demand and holiday logistics.
- Freight and raw material shifts altered the Rifaximin Production Cost Trend, applying upward pressure overall.
- Global procurement pauses and domestic restocking shaped the Rifaximin Demand Outlook, leaving volumes steady, cautious.
- Export variability and occasional sailing cancellations affected distribution and reflected in the Rifaximin Price Index.
- Manufacturers sustained production alignment with orders, avoiding overstocking while maintaining offers and margin stability overall.
Why did the price of Rifaximin change in September 2025 in APAC?
- Mild export restocking and steady domestic procurement increased demand slightly, supporting marginal net price gains.
- Container freight cost increases added logistical expense, prompting suppliers to pass through limited cost recoveries.
- Domestic manufacturing stability prevented oversupply despite softer external orders, balancing market and preventing larger declines.
Europe
- In Germany, the Rifaximin Price Index rose by 0.10% quarter-over-quarter, in Q3 2025, reflecting logistical stability and procurement restraint.
- The average Rifaximin price for the quarter was approximately USD 263740.00/MT, based on reported CFR Hamburg shipments.
- Rifaximin Spot Price remained muted, and the Rifaximin Price Index showed minimal upward pressure amid cautious buying.
- Rifaximin Price Forecast indicates marginal gains through Q4 as logistics normalize and selective forward buying supports modest firmness.
- Rifaximin Production Cost Trend remained steady with limited feedstock or manufacturing cost escalation influencing list prices modestly.
- Rifaximin Demand Outlook stays stable; hospitals and pharmacies maintain short-cycle orders, avoiding speculative bulk procurement.
- Inventory buffers across German warehouses dampened volatility while export demand remained limited, keeping spot offers subdued.
- Major producer maintenance and selective Chinese offloads influenced offers, while port congestion adjustments limited shipment frequency.
Why did the price of Rifaximin change in September 2025 in Europe?
- Moderate port congestion delayed shipments slightly, creating mild supply timing issues without substantial shortages overall.
- Freight schedule variability and carrier re-routing increased logistical costs, prompting cautious procurement and timing adjustments.
- Adequate inventories and restrained forward buying prevented sharp price moves despite shipping and geopolitical risks.
For the Quarter Ending June 2025
North America
- The Rifaximin Price Index in the USA declined by 0.81% in April, followed by marginal gains of 0.20% in May and 0.07% in June, with spot prices moving from USD 263,100/MT in April to USD 263,807/MT in June.
- In April, product spot price weakened as downstream buyers reduced orders due to high inventories, and suppliers cut prices to clear stock.
- Elevated tariffs (145%) on Chinese imports prompted pre-shipment strategies that created excess stock, suppressing demand and weighing down the price index.
- The April product demand outlook was bearish, with buyers pausing new orders amid tariff uncertainty and high inventories.
- May saw a minor rebound as the 90-day tariff suspension encouraged cautious forward-buying, contributing to upward movement in the product spot price.
- Rising freight costs, peak season surcharges, and equipment shortages in May supported a modest increase in the product price forecast.
- In June, Rifaximin prices stayed relatively flat; market stability reflected balanced supply and moderate forward purchasing.
- Ongoing U.S.–China policy concerns in June led some buyers to mildly frontload, anticipating Q3 logistics disruptions.
- Domestic demand remained stable across all Q2 months, especially in the GI and infectious disease segments.
- For July 2025, the product price forecast leans toward an increase, driven by expected port congestion, delayed shipments, and cautious procurement behavior.
APAC
- The Rifaximin Price Index in China fell by 0.77% in April, followed by a marginal uptick of 0.19% in May and 0.05% in June. This reflects a near-stable quarter shaped by subdued demand and moderate supply conditions.
- In April, the product spot price dropped due to weak international demand, mounting backlogs, and export hurdles stemming from 145% U.S. tariffs, which sharply impacted Chinese pharmaceutical competitiveness.
- Ongoing inventory overhangs and order cancellations from the U.S. led suppliers to offer aggressive discounts, driving down prices despite adequate availability—highlighting a negative product demand outlook at the start of Q2.
- China’s manufacturing contraction in April (PMI at 49.0) worsened port congestion and disrupted logistics, further reducing seller flexibility and dampening Rifaximin’s price index.
- In May, product spot prices rebounded slightly to RMB 263,500/MT as freight disruptions persisted, but steady production post-Labour Day holidays and firm inventory coverage kept prices largely stable.
- Temporary suspension of U.S. tariffs led to modest export interest; some U.S. buyers resumed procurement to rebuild stocks, creating a neutral product demand outlook without prompting a sharp shift in prices.
- By June, the price index rose marginally amid forward ordering by international clients and manageable supply levels, while logistics-related freight increases nudged exporters to adjust prices modestly.
- June saw steady production cost trends with no major imbalances, as Chinese manufacturers aligned output to demand, maintaining calm market dynamics through the end of Q2.
- For July 2025, prices are likely to increase slightly, supported by steady domestic buying from formulation units, moderate overseas demand, and continued stability in manufacturing and logistics.
- The product price forecast suggests that manageable inventories and stable factory operations will maintain supply-side discipline, while forward ordering and regular restocking offer modest price support.
Europe
- The Rifaximin Price Index in Germany declined by 0.77% in April 2025, reaching USD 263,087/MT, pressured by oversupply caused by US tariff redirections and subdued domestic demand.
- Product spot price dropped sharply in April due to increased volumes redirected from the US to Germany and pre-stocking ahead of the May holidays, leaving buyers with surplus inventories.
- Product demand outlook remained weak in April as buyers held off purchases amid congestion at ports like Hamburg and Rotterdam, while pharma procurement activity stayed flat.
- In May 2025, the Price Index rose marginally by 0.19% to USD 263,590/MT, reflecting a balance between stable demand and rising shipping constraints across Northern Europe.
- Although port congestion and Rhine water-level issues extended lead times in May, pre-booked shipments kept inventory levels adequate and stabilized product spot price movements.
